Prostate Cell News

Prostate Cell News is an online resource summarizing the latest prostate cell research.

Neuromedin U ‘Innervation’ Reprograms Myeloid Immunosuppression in Neuroendocrine Prostate Cancer

September 4, 2026

[Oncogene] Using a transgenic mouse model, researchers showed that early stages of neuroendocrine prostate cancer are associated with increased intraprostatic recruitment of Ly6G+ polymorphonuclear neutrophils and reduced infiltration of CD8+ T cells.

UCLA Engineer Neil Lin Receives $2.1M DOD Grant to Develop AI “Digital Twins” Targeting Treatment-Resistant Prostate Cancer

September 4, 2026

[UCLA Samueli School of Engineering] The US Department of Defense has awarded a four-year, $2.1 million grant to a research team led by Dr. Neil Lin at the UCLA Samueli School of Engineering. The funding will support a new approach merging genetic testing, functional drug-sensitivity testing and advanced computer modeling into a single system for guiding prostate cancer therapy.

Glutamine Synthesis Pathway Promotes the Survival and Recurrence of Dormant Tumor Cells in Prostate Cancer

September 4, 2026

[Cell Death Discovery] Investigators reported that the glutamine synthesis pathway is required for cellular dormancy under androgen-deprived conditions. The key enzyme, glutamine synthetase, is upregulated during hormonal therapy, which leads to overabundant glutamine as a nutrient and an energy storage for tumor recurrence.

Castration-Resistant Prostate Cancer Cells Are Addicted to the High Activity of Cyclin-Dependent Kinase 2

September 4, 2026

[Molecular Oncology] Scientists developed a CDK2 inhibitor-resistant CRPC model and performed a rational compound screen to assess which of the currently used anti-CRPC treatments could augment CDK2 therapy-response.

MYC-Sensitized Cuproptosis Combined with PTT to Remodel the Immune Microenvironment of Prostate Cancer

September 4, 2026

[Cancer Immunology Research] Researchers fabricated a targeted nanoplatform (CuS@MYC-PEG-FA) to achieve a synergistic cuproptosis and immunotherapy. The results showed that the combination of CuS@MYC-PEG-FA and PD-L1 inhibitor treatment can significantly inhibit the development of prostate cancer.

A THBS2+ Cancer-Associated Fibroblast Subpopulation Orchestrates Therapeutic Resistance in Castration-Resistant Prostate Cancer

September 4, 2026

[Scientific Reports] Researchers comprehensively characterized the stromal alterations driving CRPC, with a focus on heterogeneous cancer-associated fibroblast subpopulations.

Hippo-YAP1 Dysregulation Contributes to Cigarette Smoke-Induced Prostate Cancer Stemness, Reversed by Metformin

September 4, 2026

[Scientific Reports] Through integrative in vitro and in vivo analyses, combined with genetic manipulation of YAP1, researchers demonstrated that cigarette smoke extract induces YAP1 nuclear translocation and upregulates stemness-associated genes.

Oxygen-Generating Cryogel Vaccines Help Overcome Tumor Antigen Tolerance and Induce Durable Antitumor Immunity in Prostate Cancer

September 4, 2026

[Cell Biomaterials] Researchers showed that an O2-generating platform, Click O2-CryogelVAX, targeting the tumor-associated antigen prostatic acid phosphatase, enhances adaptive immune responses and provides strong therapeutic benefits in a prostate cancer model.

The Gut-Prostate Axis in Benign Prostatic Diseases: Mechanistic Pathways and Therapeutic Implications

September 4, 2026

[iScience] The authors summarize the evidence linking the gut microbiota to benign prostatic diseases, examine potential mechanisms, and discuss clinical translational value.

Hypoxia-Responsive HIF-1α-Dependent RhoA Signaling Promotes Motility and Aerotaxis in Polyaneuploid PC3 Cancer Cells with Increased Nuclear Rounding

September 4, 2026

[Biophysical Journal] Investigators showed that under extreme self-generated hypoxia, the polyaneuploid subset of PC3 prostate cancer cells upregulates a hypoxia-responsive, HIF-1α-dependent RhoA signaling axis that promotes aerotaxis, a behavior predictive of intravasation during metastasis.

NAT10 Promotes Prostate Cancer Progression by Acetylating mRNA of MARK2 and Activating mTOR/HIF-1α/C-Myc Pathway to Enhance Glycolytic Reprogramming

August 21, 2026

[Cancer Gene Therapy] Researchers discovered a pronounced overexpression of NAT10 in prostate cancer tissues and cell lines, which correlated with enhanced cellular proliferation, migration, invasion, and overall tumor growth.

Dual Downregulation of HRK and BAD Promotes BCL-Xl-Mediated Docetaxel Resistance in Prostate Cancer

August 21, 2026

[Oncogenesis] Scientists elucidated that BCL-xL is the major pro-survival protein in prostate cancer cell lines after docetaxel treatment, which can be reverted using BH3 mimetics or PROTAC strategies against this protein.

Published since 2010, Prostate Cell News compiles top scientific journal articles covering the characterization, behavior, and culturing of prostate cells. Additionally, our editorial team curates the latest press releases, technical advances, jobs, and events relevant to the prostate cell research community. Prostate Cell News saves scientists valuable time while keeping them informed in their field, facilitating the rapid exchange of cutting edge research updates and science news.